Sudeep Pharma Ltd
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]
- Market Cap ₹ 7,872 Cr.
- Current Price ₹ 697
- High / Low ₹ 796 / 524
- Stock P/E 45.5
- Book Value ₹ 78.2
- Dividend Yield 0.00 %
- ROCE 28.1 %
- ROE 25.2 %
- Face Value ₹ 1.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.3%
Cons
- Stock is trading at 8.91 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 123 | 215 | 343 | 459 | 502 | 642 | |
| 98 | 171 | 276 | 277 | 311 | 420 | |
| Operating Profit | 25 | 44 | 67 | 182 | 191 | 222 |
| OPM % | 21% | 20% | 20% | 40% | 38% | 35% |
| 3 | 3 | 7 | 6 | 9 | 29 | |
| Interest | 1 | 1 | 2 | 5 | 7 | 8 |
| Depreciation | 3 | 4 | 5 | 9 | 11 | 15 |
| Profit before tax | 25 | 43 | 69 | 175 | 183 | 228 |
| Tax % | 27% | 22% | 27% | 24% | 24% | 24% |
| 18 | 33 | 50 | 133 | 139 | 174 | |
| EPS in Rs | 128.02 | 236.60 | 356.04 | 945.36 | 14.27 | 15.31 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | % |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 39% |
| 3 Years: | % |
| TTM: | 25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 30% |
| Last Year: | 25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 10 | 11 |
| Reserves | 80 | 113 | 162 | 355 | 481 | 872 |
| 20 | 31 | 84 | 78 | 140 | 150 | |
| 30 | 67 | 97 | 80 | 86 | 141 | |
| Total Liabilities | 131 | 213 | 344 | 514 | 717 | 1,175 |
| 60 | 68 | 137 | 180 | 189 | 344 | |
| CWIP | 8 | 24 | 8 | 45 | 88 | 178 |
| Investments | 6 | 19 | 0 | 0 | 0 | 0 |
| 57 | 102 | 199 | 289 | 439 | 653 | |
| Total Assets | 131 | 213 | 344 | 514 | 717 | 1,175 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 10 | 35 | -3 | 66 | 49 | ||
| -22 | -40 | -38 | -49 | -79 | ||
| 12 | 13 | 51 | -13 | 53 | ||
| Net Cash Flow | -0 | 8 | 10 | 4 | 23 | |
| Free Cash Flow | 1 | 24 | -77 | 13 | -15 | |
| CFO/OP | 62% | 104% | 22% | 61% | 47% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 115 | 135 | 129 |
| Inventory Days | 77 | 79 | 104 | 150 | 309 | 347 |
| Days Payable | 70 | 79 | 76 | 115 | 145 | 110 |
| Cash Conversion Cycle | 97 | 93 | 142 | 151 | 298 | 366 |
| Working Capital Days | 46 | 13 | 30 | 99 | 144 | 175 |
| ROCE % | 36% | 36% | 36% | 28% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Total Annual Installed Capacity Metric Tons (MT) |
|
||||
| Consolidated Capacity Utilization % |
|||||
| Net Working Capital Days Days |
|||||
| Sales Volume - Pharma, Food & Nutrition Metric Tons (MT) |
|||||
| Sales Volume - Specialty Ingredients Metric Tons (MT) |
|||||
| Total Actual Production Volume Metric Tons (MT) |
|||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 May
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
22 May - Audio recording of 22 May 2026 earnings call uploaded online; transcript to follow.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 22 May
- Announcement under Regulation 30 (LODR)-Investor Presentation 21 May
-
Announcement under Regulation 30 (LODR)-Dividend Updates
21 May - Board approved FY26 audited results, recommended Rs.1.50 final dividend, and appointed cost and secretarial auditors.
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Feb 2026Transcript PPT
-
Dec 2025Transcript PPT
Company Overview[1]
Sudeep Pharma Limited is a leading manufacturer of excipients and specialty ingredients catering to the pharmaceutical, food, and nutrition industries. The company has evolved from producing basic excipients to offering a broad portfolio of over 100 products, serving more than 1,100 customers globally. Its mineral-based ingredients, including calcium, zinc, iron, and magnesium salts, are widely used in formulations across health, nutrition, and food applications.